Blueprint Medicines Inc., of Cambridge, Mass., disclosed new preclinical data demonstrating that its drug candidate BLU-285 has significant anti-tumor activity in treatment-resistant models of gastrointestinal stromal tumors and achieved and maintained complete tumor regression in all mice treated at the highest dose level.